FDA warns Korean drugmaker for repeat violations

Oct 19, 2018

The U.S. FDA issued South Korea-based Hanlim Pharm a warning letter over poor aseptic practices and inadequate processes for documentation, among other violations of good manufacturing practice (GMP).

Based on findings from a facility inspection in late January/early February of this year, the warning noted poor aseptic practices, inadequate design of aseptic lines, failure to monitoring environmental conditions in aseptic processing areas, as well as numerous data integrity and security issues.

Similar GMP violations had been observed during FDA visits to the Gyeonggi-do site in 2014 and 2016.

The FDA requested that Hanlim respond to the cited violations by providing a risk assessment on aseptic technique and cleanroom behavior, and an investigation into the extent of the inaccuracies seen in data records and reporting, among other corrective and preventive actions prior to consider lifting of the import alert the agency placed on the company in May.

Read the Warning Letter
Read the RAPS coverage

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments